Past Trial 11

Past Trial

A Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design with Repeated Doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 6-Month Open Label Follow-Up Period.

keyboard_arrow_up